VALENTINA ALICE CAUDA

Download the vcard Photo

Associate Professor

+39 0110907389 / 7389 (DISAT)

Personal web site

Most recent publications

Alfieri, Francesca; Ancona, Andrea; Tripepi, Giovanni; Crosetto, Dario; Randazzo, ... (2021)
A deep-learning model to continuously predict severe acute kidney injury based on urine output changes in critically ill patients. In: JN. JOURNAL OF NEPHROLOGY. ISSN 1121-8428 Download fulltext
Pietricola, Giuseppe; Tommasi, Tonia; Dosa, Melodj; Camelin, Enrico; Berruto, Emanuele; ... (2021)
Synthesis and characterization of ordered mesoporous silicas for the immobilization of formate dehydrogenase (FDH). In: INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 177, pp. 261-270. ISSN 0141-8130
Carminna, Ottone; Pugliese, Diego; Laurenti, Marco; Simelys, Hernandez; Cauda, Valentina ... (2021)
ZnO Materials as Effective Anodes for the Photoelectrochemical Regeneration of Enzymatically Active NAD+. In: ACS APPLIED MATERIALS & INTERFACES, vol. 13, pp. 10719-10727. ISSN 1944-8244 Download fulltext
Susa, F.; Bucca, G.; Limongi, T.; Cauda, V.; Pisano, R. (2021)
Enhancing the preservation of liposomes: The role of cryoprotectants, lipid formulations and freezing approaches. In: CRYOBIOLOGY, vol. 98, pp. 46-56. ISSN 0011-2240
Racca, L.; Cauda, V. (2021)
Remotely Activated Nanoparticles for Anticancer Therapy. In: NANO-MICRO LETTERS, vol. 13, pp. 1-34. ISSN 2311-6706 Download fulltext
Cauda, Valentina Alice; Canavese, Giancarlo; Limongi, Tania; Garino, Nadia; Laurenti, ... (2020)
BIOMIMETIC NON - IMMUNOGENIC NANOASSEMBLY FOR THE ANTITUMOR THERAPY. N. brevetto: US 20200330616A1, propr. brevetto: Politecnico di Torino Download fulltext
Cauda, Valentina Alice (2020)
Multimodal hybrid and theranostic nanoparticles as smart Trojan horses to fight cancer. In: THE PROJECT REPOSITORY JOURNAL, vol. 6, pp. 108-110. ISSN 2632-4067 Download fulltext
Laurenti, M.; Grochowicz, M.; Dragoni, E.; Carofiglio, M.; Limongi, T.; Cauda, V. (2020)
Biodegradable and drug-eluting inorganic composites based on mesoporous zinc oxide for urinary stent applications. In: MATERIALS, vol. 13. ISSN 1996-1944 Download fulltext
Villata, S.; Canta, M.; Cauda, V. (2020)
Evs and bioengineering: From cellular products to engineered nanomachines. In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21. ISSN 1661-6596 Download fulltext
Carofiglio, M.; Barui, S.; Cauda, V.; Laurenti, M. (2020)
Doped zinc oxide nanoparticles: Synthesis, characterization and potential use in nanomedicine. In: APPLIED SCIENCES, vol. 10. ISSN 2076-3417 Download fulltext
Battaglini, Matteo; Marino, Attilio; Carmignani, Alessio; Tapeinos, Christos; Cauda, ... (2020)
Polydopamine nanoparticles as an organic and biodegradable multitasking tool for neuroprotection and remote neuronal stimulation. In: ACS APPLIED MATERIALS & INTERFACES, vol. 12, pp. 35782-35798. ISSN 1944-8244
Venkatesh, C.; Laurenti, M.; Bandeira, M.; Lanzagorta, E.; Lucherini, L.; Cauda, V.; ... (2020)
Biodegradation and antimicrobial properties of zinc oxide–polymer composite materials for urinary stent applications. In: COATINGS, vol. 10. ISSN 2079-6412 Download fulltext
Cauda, V.; Canavese, G. (2020)
Mesoporous materials for drug delivery and theranostics. In: PHARMACEUTICS, vol. 12, pp. 1-3. ISSN 1999-4923 Download fulltext
Matos, J. C.; Laurenti, M.; Vighetto, V.; Pereira, L. C. J.; Waerenborgh, J. C.; ... (2020)
Biomimetic amorphous titania nanoparticles as ultrasound responding agents to improve cavitation and ros production for sonodynamic therapy. In: APPLIED SCIENCES, vol. 10. ISSN 2076-3417 Download fulltext
Canta, M.; Cauda, V. (2020)
The investigation of the parameters affecting the ZnO nanoparticle cytotoxicity behaviour: A tutorial review. In: BIOMATERIALS SCIENCE, vol. 8, pp. 6157-6174. ISSN 2047-4830
Cauda, V.; Limongi, T.; Racca, L.; Canta, M.; Susa, F.; Piva, R.; Bergaggio, E.; Vitale, ... (2019)
Vettore nanoporoso biomimetico comprendente un inibitore diretto verso la forma nativa della proteina IDH2. N. brevetto: IT102019000001009, propr. brevetto: 3 - Politecn. di Torino et al
Cauda, V.; Canavese, G.; Limongi, T.; Garino, N.; Laurenti, M.; Dumontel, B.; Canta, M.; ... (2019)
Biomimetic Non-Immunogenic Nanoassembly for the Antitumor Therapy. N. brevetto: 18807126.0-1109, propr. brevetto: 2 -Autori del brevetto Download fulltext
Cauda, V.; Cicero, G.; Canavese, G.; Limongi, T.; Garino, N.; Racca, L.; Ancona, A.; ... (2018)
Agente sonosensibilizzante e suo metodo di attivazione. N. brevetto: IT102018000009966, propr. brevetto: 3 - Politecn. di Torino et al
Onida, B.; Cauda, V.; Fiorilli, S.; Verne, E.; Brovarone, C. V.; Viterbo, D.; Croce, G.; ... (2005)
Incorporation of ordered mesoporous silica inside a bioactive porous scaffold in view of controlled drug release. In: Studies in Surface Science and Catalysis / S.N., S.L., Elsevier Inc., pp. 2027-2032
Show all publications in Porto@Iris

Funded research projects

A KEY TO THE UNDERSTANDING OF EXTRACELLULAR VESICLES AND RATIONAL DESIGN OF MIMICKING NANOPARTICLES , (2021-2025) - Responsabile Scientifico

Ricerca UE (non commerciale).

ERC sectors

LS7_1 - Medical engineering and technology LS1_11 - Biochemistry and molecular mechanisms of signal transduction LS1_6 - Lipid synthesis, modification and turnover LS1_8 - Biophysics (e.g. transport mechanisms, bioenergetics, fluorescence) LS1_1 - Molecular interactions

SDG

Obiettivo 3. Assicurare la salute e il benessere per tutti e per tutte le età

Abstract

Extracellular vesicles (EVs) are nowadays well known as small vesicles (< 1µm) produced by almost all cell types, ensuring efficient communication among cells throughout the body, by transporting molecules and nucleic acids. Actually, they contain cell-type specific signatures and have been proposed as biomarkers in a variety of diseases. Therefore, the species exposed at the external surface or incorporated in the lumen have a strategic importance for EV biological functions; however, their role and related functions are still not entirely clear and are topic of current research. With the MIMIC-KeY project we propose a radical change of paradigm to understand and predict the behaviour of natural EVs and then design and produce synthetic EV-mimicking nanoparticles.

Departments

Expand details

Fighting cancer relapse with remote activation of smart and targeted nanoconstructs (XtraUS), (2021-2022) - Responsabile Scientifico

Ricerca UE (non commerciale).

ERC sectors

LS7_3 - Pharmacology, pharmacogenomics, drug discovery and design, drug therapy LS7_1 - Medical engineering and technology

SDG

Obiettivo 3. Assicurare la salute e il benessere per tutti e per tutte le età

Abstract

This project XtraUS focuses on the prevention of cancer relapse and on the achievement of an early cure of recurrence, thus having a heavy impact on health and on its financial implications. Actually, many patients unfortunately get into a recurrence of their disease, since their cancer is not fully remitted and they require further treatment to manage it. Minimal residual disease (MRD) after potentially curative treatment generally contributes to disease relapse and to be the target of early adjuvant treatment. In particular, circulating tumor cells (CTCs) in the blood stream have a key role in cancer progression, recurrence and metastasis spreading. From a social and financial perspective, fighting these cancer cells has a huge impact on cancer relapse prevention and thus on the health, quality of life and overall cancer treatment expenditure.XtraUS aims at validating a breakthrough technology to fight CTCs in the bloodstream and thus reduce the rise of MRD and further cancer relapse. It applies an extracorporeal blood circulation set-up exploiting a novel stimuli-responsive, targeted and non-immunogenic nanoconstruct, remotely activated against CTCs. XtraUS results in a personalized and translational approach, with high-target specificity and reduced collateral damage to both blood and adjacent healthy tissues. With this technology, we aim to advance the conventional treatments of CTCs in the blood stream, proposing a more effective and safer treatment to fight cancer relapse and metastasis spreading. The driving idea is to render permanent and efficacious the first treatment offered to patients for their primary tumor disease, avoid cancer relapse, and reduce all associated costs. Moreover, XtraUS is a versatile technology, with potential applications also on many other pathologies, with huge societal and economic impacts on public health.

Departments

Expand details

Sviluppo di algoritmi di AI per la predizione di insorgenza di insufficienza renale acuta, (2020-2021) - Responsabile Scientifico

Ricerca Commerciale. Consulenze e Contratti di ricerca

Countries

  • ITALIA

Institutes/Companies

  • NOVASIS INNOVAZIONE SRL

Departments

Expand details

Composizione farmacologica per massimizzare l’efficacia terapeutica degli inibitori del proteasoma, (2020-2021) - Responsabile Scientifico

Ricerca da Enti privati e Fondazioni (non commerciale).

ERC sectors

LS7_3 - Pharmacology, pharmacogenomics, drug discovery and design, drug therapy

SDG

Obiettivo 3. Assicurare la salute e il benessere per tutti e per tutte le età

Abstract

Gli inibitori del proteasoma (IP) sono ampiamente utilizzati per il trattamento del mieloma multiplo (MM) e del linfoma mantellare (MCL). Tuttavia, le ricadute, la resistenza innata e le progressioni della malattia sono frequenti nei pazienti di MM. Recentemente, è stata proposta una nuova combinazione sinergica, in grado di aumentare l’efficacia degli IP, in particolare contro MM, MCL e linfoma di Burkitt (BL). La letalità sintetica (LS) è l’interazione tra due geni coessenziali la cui singola inibizione mantiene la cellula in vita, ma la cui inibizione congiunta produce morte cellulare. Il fenomeno di LS è già sfruttato clinicamente, ma la sua efficacia è limitata dalla ridotta biodisponibilità e dall’idrofobicità delle molecole usate. Gli autori hanno recentemente rivestito nanoparticelle (NP) di silici mesoporose (SM) con doppi strati fosfolipidici (DSL) di origine commerciale e artificiale, dando origine a innovative vescicole liposomali (chiamate anche “protocells”) ingegnerizzate per il drug delivery intracellulare e dotate di agenti di targeting. Tali NP possono diventare “proiettili di LS” capaci di incorporare agenti antitumorali e di targeting con un’elevata efficienza di rilascio. Tali nanocostrutti SM@DSL permettono il trasporto efficiente senza off-target e perdite incontrollate di farmaco, la concentrazione del/dei farmaco/i all’interno del nanocostrutto e il rilascio controllato intracellulare di tali farmaci. Infine, possono essere equipaggiati con anticorpi monoclonali (mAb) per un targeting efficace delle cellule bersaglio. Lo sviluppo di tale tecnologia soddisfa i seguenti bisogni:- massimizzare l’efficacia di LS con una formulazione farmacologica veicolata da SM@DSL-mAb, superando le attuali limitazioni dei farmaci utilizzati e aumentandone la selettività - recuperare il farmaco AGI-6780, già approvato ma escluso dalla traslazione clinica per bassa biodistribuzione- migliorare le cure contro il cancro

Countries

  • ITALIA

Departments

Expand details

Multifunctional Immunocompatible NanoTheranostics to modulate tumor microenvironment and improve treatment monitoring: A double blow to pancreatic cancer, (2019-2021) - Responsabile Scientifico

Ricerca UE (non commerciale). Progetti di Ricerca Europei

Abstract

Different nanomaterials were developed so far in particular against cancer, paid very little attention to their potential immunogenicity, to their final destiny, as well as to the importance of zero-delivery in unwanted places. Thus, there is still a huge disproportion between the present nanomedicine tools and the clinical requirements. The ambitious purpose of the MINT project is to develop immunocompatible tumor targeted zinc oxide nanocrystals (ZnO-NCs) coated by extracellular vesicles (EVs) with enhanced drug delivery capabilities to cancer cells, by disturbing the supportive tumor microenvironment of pancreatic cancer, one of the most lethal human malignancies. Moreover, ZnONCs is doped with transition metal elements to be probed for treatment monitoring. In recent years while several therapeutic advances were implemented in many cancer types, the scenario of pancreatic cancer remains unchanged. The main factor behind the limited efficacy of chemotherapeutics in pancreatic cancer is its complex microenvironment. We propose to deliver Hedgehog pathway inhibitor & vascular endothelial growth factor receptor kinase inhibitor simultaneously through the multifunctional EV-coated doped ZnO-NCs to deplete tumor stroma, normalize tumor vascularity and improve pancreatic cancer therapeutic index. The proposed Fellowship will enable a highly interdisciplinary collaboration between the Researcher, experienced in targeted therapy & pancreatic cancer biology, and the supervisor, pioneer in designing nanotheranostics. These working conditions will effectively promote the Researcher’s professional development, providing her with excellent new expertise in nanotheranostics and fundamental leadership skills, significantly widening her career perspectives. The project outcomes will be of tremendous benefit to the European biomedical sectors, bridge the current gap between the conventional therapies and the Frontier research in the field of cancer nanomedicine.

Countries

  • ITALIA

Departments

Expand details

Hybrid immune-eluding nanocrystals as smart and active theranostic weapons againstcancer, (2016-2021) - Responsabile Scientifico

Ricerca UE (non commerciale). Progetti di Ricerca Europei

Abstract

This project aims to develop a new generation of multifunctional therapeutic and diagnostic (thus theranostics)nanosystems displaying non-immunogenicity, improved cancer treatment, cell imaging, and high safety for the hostingorganism. The innovative concept behind this approach relies on a core-shell nanosystem with a therapeutically activecore, i.e. a TrojaNanoHorse (TNH), here validated against leukaemia. The injectable TNH have a lipid bilayer shell derivedfrom autologous cancer cell membrane, naturally non-immunogenic. The hemocompatibility, anti-thrombogenicity, andtargeting ability with antibody toward malignant blood cells will be proved during this project. Studies will show thenanocrystal core activation by ultrasound, developing toxic reactive oxygen species (ROS) for cancer killing, and its greenfluorescence emission. The whole TNH would go beyond the state-of-the-art due to its nature-derived biomimetic shell,absence of drugs, its safety and biodegrading fate, and green and sonoluminescent emissions for diagnosis. This projectwill also develop novel set-up for ultrasound-based therapy and diagnosis, impacting on future technology, newstandardized protocols for nanomaterial safety assessment, and study chemical and biological mechanism of echogenicROS development and cavitation effects on cancer cell. Achieving the ultimate goal of a multifunctional TNH will requiremultidisciplinary expertise in chemistry, material science, biology, medicine and engineering, opening new horizons asnanomedicine tools for efficient cancer therapy with strong scientific, technological and socio-economic benefits.

Countries

  • BELGIO
  • ITALIA

Institutes/Companies

  • COMMISSIONE EUROPEA

Departments

Expand details